Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

131.47 -2.46 (-1.83%)
Streaming Delayed Price Updated: 2:42 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
Via Benzinga
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
Via Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
Via Benzinga
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
Via Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Via Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
Via Benzinga
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
Wall Street Journal 
Via Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
Via Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
Via Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
Via Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
Via Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
Via Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress. 
Via Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
Via Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ: 
Via Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
Via Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
Via Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Via Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Via Benzinga
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
Via Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Via Benzinga
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.  
Via Benzinga
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance
Via Benzinga
Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments
Via Benzinga
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.